Recap: Deciphera Pharmaceuticals Q4 Earnings

Shares of Deciphera Pharmaceuticals DCPH were unchanged in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were up 16.03% year over year to ($1.10), which beat the estimate of ($1.15).

Revenue of $19,486,000 rose by 0.00% from the same period last year, which beat the estimate of $18,930,000.

Outlook

Deciphera Pharmaceuticals hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Feb 09, 2021

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/4mtugm7p

Price Action

Company's 52-week high was at $71.11

52-week low: $33.10

Price action over last quarter: down 19.99%

Company Profile

Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations are functioned through the region of US.